Nicely written assessment kelvin8r, thanks for posting.

First 15 Last

Share
Profile

Follow
Bluebush

2,285 Posts.

307

20/03/24

16:10

Post #: 72979812
Share

Originally posted by Kelvin8r ↑

Some info and context ive received today...

Imugene has ended its collaboration with Arovella with over the CD19-iNKT / onCARlytics program.

The program was initiated 18 months ago,before Arovella expanded its own armoured solid tumour therapy range and before Imugene acquiring their modified CD19-CAR-T drug azer-cel for US$220m.

Imugene expects azer-cel to work effectively as an off-the-shelf CAR-T for blood cancers, like Arovella’s CD19-iNKT drug. Both components for the azercel/onCARlytics combination are in individual phase 1 clinical trials. Imugene is due to start trials for the combined drugs imminently (announced 11/03/2024).

From a recent research report: “Imugenes recent acquisition of Precision Biosciences’ allogeneic CAR T cell therapy,azer-cel is a major addition to its pipeline that complements Imugene’s onCARlytics program. While azer-cel continues to progress for r/r NHL patients in clinical trials, the acquisition allows Imugene to develop its own combination solution in multiple hard-to-treat solid tumor indications. This enables the company to streamline R&D, manufacturing, marketing, and distribution processes, eliminating reliance on third parties, potentially leading to significant cost saving to market.”

There have been no reports of Imugene cancelling a collaboration with Celulartity’s CYCART-19, an allogeneic CD19-CAR-T drug at a similar stage to Arovella’s ALA101. This raises the question of why one and not the other. With this decision, and after very positive “test tube” data, we won’t see the data from the ALA/IMU mouse trial collaboration to potentially help understand the decision for one and not the other.

As Imugene had no options over Arovella’s CD19-iNKT drug, which was used in the collaboration, this appears to be a strategic decision to protect their acquisition from the competition of other off-the-shelf drugs.

Expand

Nicely written assessment kelvin8r, thanks for posting.

ALA Price at posting: 12.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

There are more pages in this discussion • 48 more messages in this thread...

First 15 Last

Add ALA (ASX) to my watchlist

(20min delay)
Last 12.5¢		Change 0.000(0.00%)		Mkt cap ! $131.2M

Open	High	Low	Value	Volume
12.5¢	12.5¢	12.0¢	$130.6K	1.049M

Buyers (Bids)

No.	Vol.	Price($)
11	494725	12.0¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	29845	6

View Market Depth

No.	Vol.	Price($)
11	494725	0.120
11	415800	0.115
11	552672	0.110
11	501529	0.105
19	732920	0.100

Price($)	Vol.	No.
0.125	29845	6
0.130	1260444	12
0.135	2316065	8
0.140	689157	12
0.145	28615	2

Last trade - 16.10pm 09/05/2024 (20 minute delay)


Last 12.5¢		Change 0.000 ( 4.17 %)
Open	High	Low	Volume
12.5¢	12.5¢	12.0¢	528422
Last updated 15.22pm 09/05/2024 ?

ALA (ASX) Chart

Nicely written assessment kelvin8r, thanks for posting.

Featured News

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

UNITH's digital humans expand into Amazon; Facebook

CBA profits fall 3% in March quarter but funding portfolio is flourishing

Recce breathes better on positive lung infection drug pilot test results

Raiden opens door to private Mallina in win-win Arrow Gold divestment

Buyers (Bids)

Sellers (Offers)

Featured News

Nicely written assessment kelvin8r, thanks for posting.

Featured News

Top Stories

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

UNITH's digital humans expand into Amazon; Facebook

CBA profits fall 3% in March quarter but funding portfolio is flourishing

Recce breathes better on positive lung infection drug pilot test results

Raiden opens door to private Mallina in win-win Arrow Gold divestment

Buyers (Bids)

Sellers (Offers)

Featured News